Recent Updates
Recently added Catalysts

TR-700

Phase 1

Healthy | Small molecule | Other |Merck & Company, Inc.|Last Updated: Nov 15, 2019

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLEDBiomarker
Total Trials1
Total Enrollment15

FDA Designations

No designations recorded

Clinical trial landscape

TR-700 · 1 trial · 1 indication

Phase 1 1
NCT00666601Microdialysis and Pharmacokinetic Study of TR-701Healthy
COMPLETED15 Analytics
PHASE1COMPLETED
Microdialysis and Pharmacokinetic Study of TR-701
HealthyUnlock trial analytics

Study Endpoints

Primary Endpoints

Subcutaneous tissue concentrations of TR-700
Single day
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeBASIC_SCIENCE

Treatment Arms

ArmTypeDescription
Pilot studyEXPERIMENTAL3 subjects, open lable, microdialysis single dose.
Main StudyEXPERIMENTAL12 subjects, open label, single dose of 600 mg.

Interventions

NameTypeDescription
TR-700 (active moiety)DRUGA TR-700 solution will be locally administered via a microdialysis probe into the skeletal muscle and subcutanous tissue (just under the skin) at a concentration of approximately 2 µg/mL at a flow rate of 1.5 µL/min for 60 minutes for a total maximum dose of 0.36 µg (0.18 µg per probe).
TR-701 (pro-drug)DRUGEach subject enrolled in the Main study will receive a single oral dose of 600mg TR-701
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 50 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Body mass index of 20 to 29 kg/m2 * Agree not to consume any products containing tobacco, alcohol, quinine, grapefruit, caffeine, or high levels of tyramine * Agree not to use any other medication * Female subjects must be postmenopausal (for at least 6 months), surgically ste...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about TR-700

What is TR-700 used for?

TR-700 is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with one completed trial involving 15 participants. The drug is not approved and remains under investigation.

Who makes TR-700?

TR-700 is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting clinical research on this investigational small molecule.

What phase is TR-700 in?

TR-700 is in Phase 1 clinical development. One Phase 1 trial has been completed, and the drug remains investigational. It has not been approved for any use.

What clinical trials is TR-700 in?

TR-700 has one completed clinical trial, NCT00666601, titled 'Microdialysis and Pharmacokinetic Study of TR-701'. This Phase 1 study enrolled 15 healthy volunteers in the United States and was completed.

Is TR-700 the same as TR-701?

TR-700 is related to TR-701, as indicated by the clinical trial title 'Microdialysis and Pharmacokinetic Study of TR-701'. The trial studies TR-700, and the connection between the two compounds is noted in the study name.